BCYC Stock Risk & Deep Value Analysis

Bicycle Therapeutics PLC

DVR Score

8.2

out of 10

Hidden Gem

The Bottom Line on BCYC

We analyzed Bicycle Therapeutics PLC using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran BCYC through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 17, 2026•Run Fresh Analysis →

📈BCYC Performance Overview3yr weekly

📊

Unlock BCYC Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

BCYC Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

High

BCYC Deep Value Analysis

Bicycle Therapeutics continues to offer a compelling, high-risk, high-reward investment opportunity due to its differentiated Bicycle® platform in oncology. While the core scientific innovation, vast market opportunity, and strategic partnerships (Novartis, Genentech) remain significant strengths, the market's current valuation of $0.35B indicates increased skepticism or slower-than-anticipated clinical progress since late 2025. BT8009 (Nectin-4) continues to advance, but the path to market leadership is long and capital-intensive. Financial health and near-term market sentiment represent increased headwinds. However, the unique modality and pipeline scalability still present substantial 10x growth potential from the current low base, assuming successful clinical execution and future funding.

BCYC Red Flags & Warning Signs

Premium

⚠
Negative or inconclusive clinical trial results for BT8009 or other pipeline assets
⚠
Increased cash burn rate leading to significant dilution through equity raises
⚠
Intensified competition from other novel oncology modalities or ADCs
⚠
Regulatory hurdles or delays in clinical development

Unlock BCYC Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

BCYC Competitive Moat Analysis

Premium

Moat Rating

Narrow

Moat Trend

Expanding

Moat Sources

1 Identified

Intangible Assets/IP (Proprietary Bicycle® platform, composition of matter, method of use patents)

The unique structural and pharmacological properties of Bicycles provide a distinct mechanism of action compared to traditional antibodies. As more clinical data validates the platform's efficacy and safety across multiple targets, the intellectual property and clinical know-how will become increasingly difficult for competitors to replicate.

BCYC Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

BCYC Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q4 2025 and Full Year 2025 Earnings Call (Estimated early-May 2026)
•Updates on BT8009 Phase 2/3 clinical development in Nectin-4 expressing cancers (H1 2026)
•Progress updates on partnered programs with Novartis and Genentech (Ongoing)

Medium-Term (6-18 months)

•Expansion of BT8009 into additional indications or geographies (H2 2026 - H1 2027)
•Initial clinical data readouts for BT5528 (EphA2) or BT7480 (CD137 agonist) (Late 2026 - 2027)
•Potential new strategic partnerships for Bicycle® platform applications (2027)

Long-Term (18+ months)

•Regulatory submission or accelerated approval pathway for BT8009 (2028-2029)
•Acquisition interest from large pharmaceutical companies seeking novel ADC technology (2028+)
•Expansion of Bicycle® platform beyond oncology into other therapeutic areas (2029+)

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

BCYC Bull Case: What Could Go Right

✓
Positive efficacy and safety data from BT8009 clinical trials
✓
Announcements of new or expanded strategic partnerships/licensing deals
✓
Financial updates indicating strong cash management and extended runway
✓
Progress of other pipeline candidates into later-stage development

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on BCYC

Create a free account to set price alerts and get notified on Telegram when BCYC hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Bicycle Therapeutics PLC (BCYC)?

As of March 17, 2026, Bicycle Therapeutics PLC has a DVR Score of 8.2 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the risk level for BCYC stock?

Our analysis rates Bicycle Therapeutics PLC's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the BCYC DVR analysis updated?

Our AI-powered analysis of Bicycle Therapeutics PLC is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 17, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.